Table 2 Association of OPN mRNA expression with selected patient and tumor characteristics
| Â | Low (NÂ =Â 407) | High (NÂ =Â 407) | p value |
|---|---|---|---|
N (%) | N (%) | ||
Age (in years) | |||
 <50 | 187 (45.9) | 159 (39.1) | 0.047 |
 ≥50 | 220 (54.1) | 248 (60.9) |  |
NPI score | |||
 Median (range) | 5.6 (3.0–7.8) | 5.5 (3.2–9.0) | 0.64 |
Treatment group | |||
 E-CMF | 69 (17.0) | 53 (13.0) | 0.18 |
 E-T-CMF | 196 (48.1) | 192 (47.2) |  |
 ET-CMF | 142 (34.9) | 162 (39.8) |  |
Menopausal status | |||
 Premenopausal | 201 (49.4) | 172 (42.3) | 0.041 |
 Postmenopausal | 206 (50.6) | 235 (57.7) |  |
Type of operation | |||
 Modified radical mastectomy | 285 (70.0) | 290 (71.3) | 0.70 |
 Breast conserving surgery | 122 (30.0) | 117 (28.7) |  |
ER/PgR status | |||
 Negative | 65 (17.2) | 98 (25.7) | 0.004 |
 Positive | 312 (82.8) | 283 (74.3) |  |
Histological grade | |||
 I–II | 211 (51.8) | 194 (47.7) | 0.23 |
 III | 196 (48.2) | 213 (52.3) |  |
Tumor size (cm) | |||
 ≤2 | 122 (30.0) | 126 (31.0) | 0.85 |
 2–5 | 235 (57.7) | 236 (58.0) |  |
 >5 | 50 (12.3) | 45 (11.0) |  |
Positive lymph nodes | |||
 1–3 nodes | 154 (37.9) | 175 (43.0) | 0.14 |
 ≥4 nodes | 252 (62.1) | 232 (57.0) |  |
Adjuvant RT | |||
 No | 80 (20.6) | 103 (25.8) | 0.081 |
 Yes | 309 (79.4) | 296 (74.2) |  |
Adjuvant HT | |||
 No | 70 (17.3) | 84 (20.7) | 0.21 |
 Yes | 335 (82.7) | 321 (79.3) |  |
Bone metastases | |||
 No | 363 (90.5) | 346 (86.7) |  |
 Yes | 38 (9.5) | 53 (13.3) | 0.090 |
HER2 statusa | |||
 Negative | 290 (75.5) | 300 (77.5) | 0.51 |
 Positive | 94 (24.5) | 87 (22.5) |  |
Ki67 protein expression | |||
 Low (<20%) | 186 (45.7) | 179 (44.0) |  |
 High (≥20%) | 221 (54.3) | 228 (56.0) | 0.62 |
Subtypes | |||
 Luminal A | 125 (33.3) | 120 (31.8) | 0.021 |
 Luminal B | 128 (34.0) | 119 (31.5) |  |
 Luminal-HER2 | 58 (15.4) | 41 (10.8) |  |
 HER2-enriched | 35 (9.3) | 43 (11.4) |  |
 Triple-negative | 30 (8.0) | 55 (14.5) |  |